Mind Medicine (MindMed) Inc. (MNMD)


-0.08 (-2.68%)
Symbol MNMD
Price $2.9
Beta 2.196
Volume Avg. 0.56M
Market Cap 110.384M
Shares () -
52 Week Range 2.12-19.95
1y Target Est -
DCF Unlevered MNMD DCF ->
DCF Levered MNMD LDCF ->
ROE -40.15% Strong Sell
ROA -33.41% Strong Sell
Operating Margin -
Debt / Equity 12.64% Neutral
P/E -1.60 Sell
P/B 0.59 Buy


Consensus EPS

Upgrades & Downgrades

Latest MNMD news

Mr. Robert Barrow
NASDAQ Capital Market

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.